Submission of Business Responsibility and Sustainability Report for the FY 2024-25 of the Company
TORNTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Torrent Pharmaceuticals has filed its Business Responsibility and Sustainability Report (BRSR) for FY 2024-25 with BSE and NSE, as required under SEBI's Listing Regulations. The report, assured by Grant Thornton Bharat LLP, covers the company's ESG performance on a standalone basis. Key highlights include a 32% reduction in Scope 1 and 2 emissions versus the 2019-20 baseline, a workforce of 15,563 employees with 8% women, and operations across 9 plants and 30 offices in India plus 16 international offices serving 50+ markets. Standalone turnover stood at ₹9,485 crore with net worth of ₹7,592 crore and paid-up capital of ₹169.23 crore. The report also discloses several GST and tax-related penalties (totalling roughly ₹3.3 crore, including a ₹2.32 crore income tax demand) along with 25 shareholder complaints and 1,576 customer complaints during the year. Employee turnover improved to 13.5% from 16.6% the previous year.
This is a routine annual compliance disclosure and is unlikely to move the stock on its own, though it showcases continued progress on ESG targets and improved employee retention. Investors may note the disclosed tax and GST penalties, though most are being appealed and individually are not material to the company's overall size.